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Acinetobacter baumannii is an opportunistic pathogen of growing concern,
as isolates are commonly multidrug resistant. While A. baumannii is most frequently
associated with pulmonary infections, a signiﬁcant proportion of clinical isolates come
from urinary sources, highlighting its uropathogenic potential. The type II secretion
system (T2SS) of commonly used model Acinetobacter strains is important for virulence
in various animal models, but the potential role of the T2SS in urinary tract infection
(UTI) remains unknown. Here, we used a catheter-associated UTI (CAUTI) model to
demonstrate that a modern urinary isolate, UPAB1, requires the T2SS for full virulence.
A proteomic screen to identify putative UPAB1 T2SS effectors revealed an uncharacterized lipoprotein with structural similarity to the intimin-invasin family, which serve as
type V secretion system (T5SS) adhesins required for the pathogenesis of several bacteria. This protein, designated InvL, lacked the b -barrel domain associated with T5SSs
but was conﬁrmed to require the T2SS for both surface localization and secretion. This
makes InvL the ﬁrst identiﬁed T2SS effector belonging to the intimin-invasin family.
InvL was conﬁrmed to be an adhesin, as the protein bound to extracellular matrix
components and mediated adhesion to urinary tract cell lines in vitro. Additionally, the
invL mutant was attenuated in the CAUTI model, indicating a role in Acinetobacter uropathogenesis. Finally, bioinformatic analyses revealed that InvL is present in nearly all
clinical isolates belonging to international clone 2, a lineage of signiﬁcant clinical importance. In all, we conclude that the T2SS substrate InvL is an adhesin required for A.
baumannii uropathogenesis.
IMPORTANCE While pathogenic Acinetobacter can cause various infections, we recently
found that 20% of clinical isolates come from urinary sources. Despite the clinical relevance of Acinetobacter as a uropathogen, few virulence factors involved in urinary tract
colonization have been deﬁned. Here, we identify a novel type II secretion system effector, InvL, which is required for full uropathogenesis by a modern urinary isolate. Although
InvL has predicted structural similarity to the intimin-invasin family of autotransporter
adhesins, InvL is predicted to be anchored to the membrane as a lipoprotein. Similar to
other invasin homologs, however, we demonstrate that InvL is a bona ﬁde adhesin capable of binding extracellular matrix components and mediating adhesion to urinary tract
cell lines. In all, this work establishes InvL as an adhesin important for Acinetobacter’s urinary tract virulence and represents the ﬁrst report of a type II secretion system effector
belonging to the intimin-invasin family.
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cinetobacter spp. belonging to the Acinetobacter calcoaceticus–Acinetobacter baumannii
(ACB) complex are opportunistic pathogens that cause diverse infections, with A. baumannii representing the most common species associated with human infection (1–3).
While A. baumannii infections can be both community and hospital acquired, nosocomial
infections in critically ill patients are common, with mortality rates reported as high as
84.3% in individuals requiring mechanical ventilation (4–7). These high mortality rates can
be largely attributed to increasing multidrug resistance among A. baumannii isolates (6, 8).
In fact, A. baumannii exhibits the highest prevalence of multidrug resistance among Gramnegative pathogens, leading the World Health Organization to classify the bacterium as a
highest priority pathogen for research and development of new treatments (8, 9). The respiratory tract is the most common site of infection by A. baumannii, with approximately
40% of the isolates derived from pulmonary infections (2, 3, 10, 11). It should be noted
though that 20% of A. baumannii isolates come from urinary tract infections (UTIs), highlighting the bacterium’s uropathogenic capacity (10, 11). However, despite the public
health relevance of A. baumannii as a uropathogen, few virulence factors required speciﬁcally for UTI have been deﬁned (10).
Bacterial virulence relies on the interaction of bacterially derived proteins with the
infected host. Gram-negative bacteria have evolved to encode complex secretion systems
to transport proteins across the bacterial envelope (12). The type II secretion system (T2SS) is
widely distributed in Gram-negative bacteria and has been implicated in the virulence of
several pathogens (13–15). T2SS effectors are translocated from the cytoplasm to the outer
membrane or into the extracellular milieu in two steps. First, the effector is transported across
the inner membrane into the periplasm via the general secretory (Sec) pathway or the twin arginine translocation (TAT) pathway (16, 17). Second, the effector is extruded through the outer
membrane secretin (designated GspD herein) via the assembly of a pseudopilus (18–22). In
Acinetobacter, the T2SS is responsible for secretion of several proteins, including the lipases
LipA, LipH, and LipAN, the protease CpaA, and the g-glutamyltransferase GGT (23–28). For A.
baumannii strain ATCC 17978, a meningitis isolate from 1951, mutation of the T2SS results in
attenuation in bacteremia and pneumonia models of infection (23, 29). Additionally, mutation
of the T2SS in Acinetobacter nosocomialis strain M2 and A. baumannii strain AB5075, musculoskeletal isolates from 1996 and 2008, respectively, results in decreased bacterial burden in
a pneumonia model of infection (24, 28). Furthermore, the Acinetobacter effectors LipAN of
strain ATCC 17978 and CpaA of strain M2 are required for full virulence in a pneumonia
model, and GGT of strain AB5075 is required for full virulence in a bacteremia model (23, 27,
28). While the T2SS and associated effectors clearly have roles in pathogenesis in multiple
models of infection, the potential function of the T2SS in Acinetobacter uropathogenesis has
not been investigated. Additionally, T2SS-dependent secretomes can differ signiﬁcantly
between strains, and these dissimilarities can lead to strain-dependent differences in virulence potential mediated by the T2SS (24, 28, 29). Therefore, evaluation of the T2SS in
diverse clinical isolates could reveal previously unrecognized effectors that may serve as
novel Acinetobacter virulence factors.
Intimate interaction of bacteria with host tissues at the site of infection is often required
for pathogenesis. Indeed, adherence to and/or invasion of host epithelial cells, mediated by
bacterial adhesins, is an essential process for the virulence of several pathogens (30). Many
adhesins are displayed on the bacterial surface in a type V secretion system (T5SS)-dependent manner (31). These T5SSs, also termed autotransporters (ATs), are proteins consisting of
two general components, a b -barrel domain, which is inserted into the outer membrane,
and a passenger domain, which uses the b -barrel for transportation to the outer surface of
the bacteria (32–34). The intimin-invasin family of ATs speciﬁcally are adhesins that consist
of an N-terminal b -barrel domain and a C-terminal passenger domain containing multiple
immunoglobulin (IG)-like domains often capped by a lectin-like domain (35, 36). Intimin is
encoded by many pathogens such as Escherichia coli and functions by binding to a type III
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FIG 1 The T2SS is required for full virulence in a murine CAUTI model. Mice were implanted with a
catheter followed by transurethral inoculation with UPAB1 WT, DgspD, or gspD1 strains. At 24 h
postinfection, mice were sacriﬁced, and bacterial burdens on the catheter (A) and in the bladder (B) were
quantiﬁed. Shown are results from at least three pooled experiments. Each data point represents an
individual mouse, the horizontal line represents the mean, and the standard error of the mean (SEM) is
indicated by error bars. *, P , 0.05; two-tailed Mann-Whitney U test; ns, not signiﬁcant.

RESULTS
The UPAB1 T2SS mutant is attenuated in the CAUTI model. To test the role of the
T2SS in uropathogenesis, we generated a UPAB1 mutant strain lacking gspD, the gene
encoding the outer membrane secretin that is essential for T2SS function. This strain was
subsequently employed in the murine CAUTI model as previously described (10). Brieﬂy, a
small piece of silicon tubing (catheter) was inserted into the urethra, and mice were transurethrally inoculated with wild-type (WT), DgspD, or complemented (gspD1) strains. At 24 h
postinfection, mice were sacriﬁced, and bacteria adhered to the catheters (Fig. 1A) and bacterial burdens in the bladders (Fig. 1B) were quantiﬁed. The DgspD mutant exhibited
decreased binding to the catheter and colonization of the bladder, with approximately 10fold fewer CFU recovered relative to WT. The catheter binding phenotype was completely
restored by genetic complementation, and the complemented strain exhibited a trend toward higher bladder burden relative to the mutant as the P value approached signiﬁcance.
These results indicate that the T2SS plays a role in Acinetobacter uropathogenesis.
A proteomic analysis identiﬁes a putative T2SS effector with structural similarity to
Yersinia invasin. To identify T2SS effectors in UPAB1, we performed a proteomic analysis
of the supernatant of WT and DgspD strains. Proteins with decreased abundance with the
mutant strain relative to WT were considered putative T2SS effectors (see Table S1 in the
supplemental material). As expected, we identiﬁed orthologs of proteins found in previous
Acinetobacter T2SS effector screens, including the most differentially identiﬁed protein, a
59-methylthioadenosine (MTA)/S-adenosylhomocysteine (SAH) nucleosidase, as well as lipases, a CSLREA domain-containing protein, GGT, and the glycoprotease CpaA (24, 28, 29).
However, we additionally identiﬁed several proteins not found in previous analyses, several of which were annotated as hypothetical proteins of unknown function.
The most differentially abundant protein of unknown function in the supernatant of WT
and DgspD strains was D1G37_RS04395. D1G37_RS04395 is a 492-amino-acid, 51.92-kDa
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secretion system (T3SS) effector, translocated intimin receptor (TIR), which is inserted into
the host membrane (37, 38). Invasin (InvA), encoded by Yersinia enterocolitica and Yersinia
pseudotuberculosis, functions by binding directly to host b 1-integrins, leading to a host
cytoskeletal rearrangement and subsequent internalization of the bacteria (39, 40). Importantly,
deletion of genes encoding intimin-invasin family proteins results in attenuation in animal models of infection (35, 36). Despite this key role that intimin-invasin family proteins play in the
pathogenesis of other bacteria, potential homologs have not been identiﬁed in Acinetobacter.
In this work, we aimed to interrogate the function of the T2SS in the recent A. baumannii
urinary clinical isolate, UPAB1, using a murine catheter-associated UTI (CAUTI) model and
deﬁne effectors potentially required for virulence (10). In this pursuit, we identify a novel
T2SS effector/intimin-invasin family protein important for Acinetobacter uropathogenesis.
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protein predicted by SignalP 5.0 to contain an N-terminal lipoprotein secretion signal (41).
Interestingly, a fold recognition analysis of D1G37_RS04395 with Phyre2 revealed the invasin
InvA of Y. pseudotuberculosis as the best match (99.7% conﬁdence; 72.0% coverage) (Fig. S1)
(42, 43). Submission of D1G37_RS04395 to I-TASSER similarly predicted structural similarity
to InvA (2.03 normalized Z score; 77.0% coverage) (44–46). Alphafold2 was then used to
generate a model of D1G37_RS04395 to compare to the known structure of InvA (Fig. 2A)
(43, 47). D1G37_RS04395 is predicted to have three IG-like domains and is capped with a Cterminal lectin-like domain that is intimately associated with the most C-terminal IG-like domain. This is comparable to the passenger domain of InvA, with the exception that InvA
contains an additional IG-like domain (43). A key difference between D1G37_RS04395 and
InvA, however, is that InvA is an autotransporter (T5SS) attached to the membrane by an Nterminal b -barrel domain, whereas D1G37_RS04395 is a putative T2SS effector predicted to
be attached to the membrane as a lipoprotein (Fig. 2B and C) (35, 36). Of note, we performed alignments of the C-terminal 440 amino acids of InvL and 483 amino acids of InvA
using LALIGN software, as these were the regions of predicted homology from our structural
analysis. This revealed an overlap of 285 amino acids with 22.5% identity and 51.2% similarity. It should be noted though that the IG-like and lectin domains of the intimin-invasin family fold similarly but have little sequence identity (36, 48). Therefore, extensive similarity at
the amino acid sequence level between the proteins was not expected. Overall, given specifically the predicted structural similarity of D1G37_RS04395 to the passenger domain of InvA,
we will refer to this protein herein as InvL (invasin-like protein).
The T2SS is required for InvL secretion and surface exposure. To conﬁrm that secretion of InvL is dependent on a functional T2SS, WT, DgspD, and gspD1 strains were transformed with a plasmid expressing invL with a His6 tag (pBAV-Apr::invL-his6). Whole-cell lysate
and supernatant fractions from the bacteria were then assessed by immunoblotting for the
presence of InvL-His6 (Fig. 3). InvL was found in the supernatant of WT and gspD1 strains,
whereas the DgspD mutant failed to secrete the protein. This conﬁrmed that InvL is a T2SS
substrate. Immunoblot analyses demonstrated that, in addition to being released into the
supernatant, InvL was cell associated (Fig. 3). As intimin-invasin family proteins function as
surface-localized adhesins, we hypothesized that cell-associated InvL is surface localized. To
test this, proteinase K susceptibility assays wherein surface-exposed proteins are degraded
and intracellular proteins are left intact were performed with bacteria expressing invL-his6.
In WT UPAB1, InvL-His6 was completely degraded with proteinase K treatment, whereas
May/June 2022 Volume 13 Issue 3

10.1128/mbio.00258-22

4

Downloaded from https://journals.asm.org/journal/mbio on 05 July 2022 by 128.252.154.28.

FIG 2 InvL has predicted structural similarity to InvA of Yersinia. (A) The crystal structure of the passenger
domain of Yersinia InvA (PDB entry 1CWV) is shown on the left, and the AlphaFold2 predicted structure of
the analogous region of InvL is pictured on the right. (B) Amino acids corresponding to subdomains of the
passenger domain of InvA and the predicted homologous region of InvL. (C) Graphic depiction of the
structure of InvA and the predicted structure of InvL; created with BioRender.com. Red, green, and blue
colors denote individual IG-like domains, and yellow denotes the C-terminal IG-like domain in intimate
contact with the lectin-like domain. b B, b -barrel domain; SP, signal peptide; OM, outer membrane.
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the intracellular control, RNA polymerase (RNAP), was not (Fig. 4A). On the contrary, treatment
with Triton X-100 and proteinase K resulted in degradation of both InvL-His6 and RNAP. These
results indicate that InvL is surface localized, consistent with its putative role as an adhesin.
Interestingly, proteinase K failed to degrade InvL-His6 expressed in the DgspD mutant, indicating the protein did not reach the surface of the bacteria (Fig. 4B). Alternatively, InvL-His6 was
readily degraded by proteinase K treatment of gspD1 (Fig. 4C), demonstrating that the T2SS is
required for InvL surface localization.
As InvL is predicted to be a lipoprotein, its identiﬁcation in the supernatant is somewhat
surprising. To further examine the form in which InvL is secreted, insoluble and soluble fractions from the supernatant of WT UPAB1 expressing invL-his6 were separated by ultracentrifugation. Immunoblot analysis of these fractions revealed that InvL was primarily found in
the insoluble fraction (Fig. S2). This localization could be due to the presence of InvL in either
lysis by-products or possibly outer membrane vesicles (OMVs). The physiological relevance
of OMVs in Acinetobacter pathobiology remains to be investigated and will be the focus of
subsequent work.
InvL binds to ECM components. We next examined whether InvL could bind to
extracellular matrix (ECM) components. First, we used enzyme-linked immunosorbent assays
(ELISAs) to investigate if InvL binds to a5b 1 integrin (Fig. 5A) and collagen V (Fig. 5B). These
molecules are the binding partners of InvA and an E. coli homolog, FdeC, respectively (39, 49,
50). We determined that InvL bound to a5b 1 integrin and collagen V with dissociation constants (Kds) of 0.38 nM and 15 m M, respectively. On the contrary, InvL did not appreciably bind
the negative control, bovine serum albumin (BSA), at the tested concentrations. Since UPAB1
colocalizes with ﬁbrinogen deposited on the catheter during CAUTI, we assessed if InvL interacts with ﬁbrinogen (10). We found that InvL bound to ﬁbrinogen with the highest afﬁnity of
all ECM components tested (Kd = 0.19 nM) (Fig. 5C). InvL, similar to InvA and FdeC, did not exhibit any signiﬁcant binding to mucin, another common ECM component (Fig. 5D).
The interaction between InvA and b 1 integrins is competitively inhibited by arginine-glycine-aspartate (RGD)-containing peptides, a motif required for the interaction of ﬁbronectin
with b 1 integrin (51–53). RGD-containing peptides also abrogated binding of InvL to a5b 1

FIG 4 The T2SS is required for InvL
his6 were treated with proteinase K
probed for InvL (a-His6) and RNAP
biological replicates were performed,
May/June 2022 Volume 13 Issue 3

surface localization. WT (A), DgspD (B), and gspD1 (C) UPAB1 cells harboring pBAV-Apr::invL(PK; 1) or left untreated (2) in the presence or absence of Triton X-100. Cells were then
by immunoblotting. Numbers to the left indicate molecular weight in kDa. At least two
yielding similar results, and a representative blot from one replicate is shown.
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FIG 3 The T2SS is required for InvL secretion. Whole-cell lysate (WCL) and supernatant (Sup) fractions from
WT, DgspD, and gspD1 UPAB1 cultures harboring pBAV-Apr::invL-his6 were probed for InvL (a-His6) and
RNAP by immunoblotting. Numbers to the left indicate molecular weight in kDa. At least two biological
replicates were performed, yielding similar results, and a representative blot from one replicate is shown.
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FIG 5 InvL binds to multiple ECM components. ELISAs were performed to assess binding of InvL to a5 b 1 integrin (A), collagen V (B), ﬁbrinogen (C), mucin (D),
or a5 b 1 integrin in the presence of RGD-containing peptide (E). BSA served as a negative binding control. Shown are the results from two biological replicates,
and SEM is indicated by error bars.

integrin (Fig. 5E), indicating that InvL and InvA bind b 1 integrins via similar mechanisms.
Together, these results demonstrate that InvL binds a5b 1 integrin, collagen V, and ﬁbrinogen in vitro.
InvL facilitates UPAB1 adhesion to bladder and kidney epithelial cells. To examine if
InvL plays a role in binding to epithelial cells relevant to the CAUTI model, we determined adhesion of UPAB1 WT, DinvL, and invL1 strains to kidney (MDCK; Fig. 6A) and bladder (5637;
Fig. 6B) cells. The DinvL strain exhibited signiﬁcantly decreased adhesion to both cell types relative to WT at a multiplicity of infection (MOI) of 1, and a similar trend toward decreased binding by the DinvL strain was observed at an MOI of 5. This phenotype was reversed in the
invL1 strain, conﬁrming a role for InvL in urinary tract epithelial adhesion.
Because Yersinia InvA can mediate epithelial cell invasion, we performed antibiotic protection assays to assess if InvL performs a similar function (54–58). However, internalization
was not observed in any of the cell lines tested, and immunoﬂuorescence assays following
epithelial cell infection conﬁrmed UPAB1 is not invasive (Fig. S3). These results are not surprising given that few publications exist regarding Acinetobacter internalization in epithelial cells,
and internalization results are highly variable depending on the strain and cell line tested (59–
64). Altogether, our results demonstrate a role for InvL in binding to diverse epithelial cell lines,
but a possible role in invasion in other strains or cells types cannot be ruled out.
InvL is required for full virulence in the CAUTI model. Given the role of InvL as an
adhesin, we tested if InvL contributes to Acinetobacter virulence in the murine CAUTI
model. Mice were implanted with a catheter followed by transurethral inoculation with
May/June 2022 Volume 13 Issue 3
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WT, DinvL, or invL1 strains. At 24 h postinfection, mice were sacriﬁced, and bacteria adhered
to the catheters (Fig. 7A) and bacterial burdens in the bladders (Fig. 7B) were quantiﬁed. The
DinvL mutant had a signiﬁcant reduction in catheter binding, exhibiting approximately a
100-fold decrease relative to the WT strain, and this phenotype was partially reversed by
genetic complementation. DinvL also had a signiﬁcant defect in bladder colonization relative
to the WT strain, with more than 10-fold reduced CFU recovered. This phenotype was also
partially complemented with the invL1 strain. The reason for partial complementation in the
CAUTI model is unknown, but this result could be due to possible differential expression of
invL in the complemented strain relative to WT bacteria. Nevertheless, these results indicate
an important role for InvL in A. baumannii uropathogenesis.
InvL is encoded by ACB complex strains and has high prevalence among international
clone 2 isolates. As virulence factors could differ among isolates, we assessed the distribution
of invL across the Acinetobacter genus. Speciﬁcally, we performed a targeted ortholog search for
invL and adjacent genes in 3,052 available genomes from the National Center for Biotechnology
Information (NCBI) RefSeq Database (65). In genomes that encode InvL, the corresponding gene
is ﬂanked by genes encoding a TIGR01244 family phosphatase (D1G37_04390 in UPAB1) and a
dihydrolipoyl dehydrogenase (D1G37_RS04400 in UPAB1) (Fig. 8A). While the microsynteny of
the two ﬂanking genes is conserved throughout ACB complex, only 74% (2,029/2,728) of the
isolates additionally harbor the invL gene. In 23% (641/2,728), a second cluster variant exists,
where the invL gene is replaced by a gene encoding a hypothetical protein (A1S_3863 in ATCC
17978). The remainder of isolates (3%; 58/2728) have no/another intervening gene. The gene

FIG 7 InvL is required for full virulence in a murine CAUTI model. Mice were implanted with a catheter
followed by transurethral inoculation with UPAB1 WT, DinvL, or invL1 strains. At 24 h postinfection, mice
were sacriﬁced and bacterial burden on the catheter (A) and in the bladder (B) were quantiﬁed. Shown are
results from at least three pooled experiments. Each data point represents an individual mouse, the
horizontal line represents the mean, and the SEM is indicated by error bars. *, P , 0.05; two-tailed MannWhitney U test.
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10.1128/mbio.00258-22

7

Downloaded from https://journals.asm.org/journal/mbio on 05 July 2022 by 128.252.154.28.

FIG 6 InvL facilitates adhesion to epithelial cells in vitro. UPAB1 WT, DinvL, and invL1 strains were
used in adhesion assays with MDCK (A) and 5637 (B) epithelial cells. The mean from six replicates is shown,
and error bars represent the SEM. *, P , 0.05; one-way ANOVA, Tukey’s test for multiple comparisons.
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FIG 8 InvL is encoded by ACB complex strains and has high prevalence in IC-2 clones. (A) InvL is encoded at a common locus in
ACB complex strains. Orthologs of InvL (top) and orthologs of A1S_3863 (bottom) are encoded at a common locus between genes
encoding a dihydrolipoyl dehydrogenase (D1G37_RS0440 in UPAB1 and A1S_2952 in ATCC 17978; blue) and a TIGR01244 family
phosphatase (D1G37_RS04390 in UPAB1 and A1S_2951 in ATCC 17978; purple). (B) Distribution of invL and A1S_3863 in
Acinetobacter. The fractions of genomes encoding InvL and A1S_3863 are reported by ACB species and international clone number.
Percentage of genomes containing each ortholog by species and international clone number are indicated to the right.

represented in the second cluster variant does not appear to be homologous to InvL. First, the
two proteins reside on opposite strands, which interferes with genetic exchange via bacterial
recombination. Second, at the amino acid sequence level, the two proteins are only 19% identical and 31% similar, and this is substantially driven by the shared presence of an N-terminal signal peptide. Third, the length and domain architecture differ between the proteins; InvL is about
100 amino acids longer, and it harbors an invasin/intimin cell-adhesion domain (IPR008964) that
is missing in the other protein. Outside the ACB complex, the gene cluster is represented in
only 216/324 (67%) of the isolates. Of these, again the majority encode InvL (157/216; 72%). The
second cluster variant is present in 32/216 (15%) of the isolates, and the remaining 13% have either no or another intervening gene. Of note, InvL distribution correlates with international
clone (IC) number, as nearly all strains belonging to IC-2, IC-4, and IC-5 groups encode InvL
(Fig. 8B). Alternatively, strains belonging to IC-1, IC-6, and IC-8 predominantly encode the second
cluster variant. As IC-2 clones are among the most commonly isolated in clinical settings, the
prevalence of InvL in these strains is intriguing (1–3, 66, 67). However, the fact that other international clones that are associated with human infection do not predominantly encode InvL (e.g.,
IC-1) implies that some other protein(s) compensates for the absence of this adhesin. In sum,
May/June 2022 Volume 13 Issue 3
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DISCUSSION
Acinetobacter has emerged as a pathogen of signiﬁcant clinical importance due to the
increasing frequency of multidrug-resistant strains identiﬁed (6, 8, 9). Approximately 20% of
isolates are derived from the urinary tract, highlighting the uropathogenic potential of A.
baumannii (10, 11). Mutation of the T2SS in the uropathogenic strain UPAB1 resulted in
decreased catheter-binding and lower burden in the bladder, indicative of a key role during
urinary tract virulence. Through a proteomic analysis, we identiﬁed a surface-exposed T2SS
effector that belongs to the intimin-invasin family, referred to here as InvL. We found that
recombinant InvL binds to host ECM components and that the UPAB1 DinvL mutant strain
has a signiﬁcant defect in binding to bladder and kidney epithelial cells. Accordingly, the
DinvL mutant was attenuated in the CAUTI model. In all, our study demonstrates the importance of the T2SS for Acinetobacter uropathogenesis and describes a novel T2SS effector,
InvL, as a previously unrecognized adhesin and virulence factor that is encoded by most
clinical isolates.
Interestingly, although protein modeling revealed structural similarity of InvL to Yersinia
InvA, InvL is unique compared to other invasin homologs. First, while canonical invasin
homologs are T5SSs, outer membrane localization of InvL is dependent on the T2SS. To our
knowledge, this is the ﬁrst report of an intimin-invasin family T2SS effector. Second, unlike
other InvA homologs, which are anchored to the outer membrane via a large N-terminal
b -barrel domain, InvL is predicted to be a lipoprotein based on the presence of a lipoprotein
secretion signal (36, 41). While the T2SS is known to secrete soluble effectors into the extracellular milieu, it has also been reported to be essential for surface localization of some lipoproteins, similar to what is reported here for InvL (68). One of the best-characterized examples is the T2SS-dependent surface localization of the lipoprotein pullulanase (PulA), a
starch-debranching enzyme of Klebsiella oxytoca (69–71). PulA, like many other lipoproteins,
is translocated from the cytoplasm to the periplasm via the Sec pathway, where processing
and acylation occur to attach the protein to the periplasmic leaﬂet of the inner membrane
(70, 72). Whereas most outer membrane lipoproteins of Gram-negative bacteria are transported from the inner membrane to the outer membrane via the localization of lipoproteins
(Lol) pathway, PulA uses the T2SS machinery (69–71). The mechanism by which the T2SS
can recognize its lipoprotein effectors and transport lipidated proteins across the periplasm
and outer membrane remains elusive. However, this report of InvL adds to the growing list
of known T2SS effectors which are surface exposed lipoproteins (68). As several of these proteins are involved in pathogenesis and key metabolic functions (e.g., SslE of E. coli and MtrC
and OmcA of Shewanella oneidensis), a better understanding of the mechanism of T2SS-dependent lipoprotein transport is needed (68, 73–78).
Interestingly, in addition to being a surface-exposed protein, we found that InvL is
secreted into the supernatant. This is somewhat surprising, as this has not been reported
with other members of the intimin-invasin family to our knowledge. Given that InvL localized to the insoluble fraction of the supernatant, it is possible that InvL is found in OMVs.
Notably, this release of a T2SS-dependent surface-associated lipoprotein into the media is
reminiscent of PulA (79, 80). However, it is unclear if PulA is associated with OMVs, and we
cannot discount the possibility that the identiﬁcation of PulA and InvL in the supernatant is
due to their localization in bacterial lysis byproducts (68). Regardless, it is tempting to speculate that secreted InvL could serve an alternative function (e.g., modulation of host responses).
However, whether InvL serves any roles other than being an adhesin is outside the scope of
this manuscript and will be the subject of future work.
Similar to other members of the intimin-invasin protein family, InvL can directly
bind to ECM components and facilitate cell adhesion. Speciﬁcally, InvL binds with high
afﬁnity to a5 b 1 integrin, collagen V, and ﬁbrinogen. a5 b 1 integrin and collagen V are
also bound by the intimin-invasin family proteins InvA and FdeC of Yersinia and E. coli,
respectively (39, 50). Interestingly though, InvA and FdeC appear to bind to a single
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deﬁned ECM component, indicating that InvL has a broader speciﬁcity. While domains/
residues required for the FdeC-collagen interaction have not been deﬁned, the interaction between InvA and b 1 integrins has been extensively studied (49, 81–85). Binding
of InvA to b 1 integrins speciﬁcally requires the C-terminal lectin-like domain, which is
present in InvL and absent from FdeC (50, 83, 85). It is tempting to speculate that the
predicted InvL lectin-like domain is involved in binding to a5 b 1 integrin and that characteristics of Ig-like domains are responsible for recognition of collagen V. However, it
should be noted that residues known to be important for the interaction between InvA
and b 1 integrins do not appear to be conserved in InvL (81–84). This is despite the observation that the interactions of InvL and InvA with a5b 1 integrin can be similarly inhibited by
RGD peptide (51–53). The low sequence identity between InvL and invasin homologs makes
it difﬁcult to accurately predict key regions of the protein required for recognition of ECM
components. The structural characterization of InvL will, in the future, provide mechanistic
insights into the interaction between InvL and the ECM.
Our characterization of InvL adds to the growing list of known Acinetobacter adhesins that facilitate binding to epithelial cells, which includes type IV pili, the Ata autotransporter, the FhaB/FhaC two-partner secretion system, and bioﬁlm-associated protein (Bap) (86–96). ECM components bound by type IV pili and Bap are not known.
However, Ata has been shown to bind with high afﬁnity to collagen (types I, III, IV, and
V), laminin, and glycosylated ﬁbronectin, and FhaBC reportedly binds to ﬁbronectin
(88, 91, 92, 95). While the collagen-binding role of InvL may be redundant with that of
Ata, InvL is the ﬁrst published Acinetobacter adhesin to bind directly to a5 b 1 integrin
or ﬁbrinogen. Additionally, InvL is now the ﬁrst known adhesin to be important for A.
baumannii UTIs. Future work will determine the roles of these known adhesins in the
multiple niches colonized by this bacterium.
While we have established that InvL is a virulence factor involved in Acinetobacter uropathogenesis, the mechanism(s) by which InvL participates in CAUTI is unknown. The fact that
we identiﬁed ﬁbrinogen as the highest-afﬁnity binding partner for InvL is particularly intriguing with respect to CAUTI. Tissue damage from catheterization results in an inﬂammatory
response that leads to increased levels of ﬁbrinogen in the bladder that ultimately coats the
catheter (97, 98). We recently showed that Acinetobacter, similar to other uropathogens such
as Enterococcus faecalis and Staphylococcus aureus, colocalizes with ﬁbrinogen on the catheter (10, 99, 100). This interaction is dependent on the virulence factors EbpA and ClfB in E.
faecalis and S. aureus, respectively (98, 99). It is tempting to speculate that InvL serves a similar function with respect to Acinetobacter catheter binding. However, future work is required
to examine if InvL mediates catheter binding via ﬁbrinogen or if the ability of InvL to associate with other ECM components is responsible for its role in the CAUTI model. Additionally,
future work is required to determine if InvL similarly serves as a virulence factor in other
infection models (e.g., pneumonia and bacteremia). Ultimately, a better understanding of A.
baumannii virulence factors such as InvL may aid in the development of novel therapeutics
to combat infection by these increasingly multidrug-resistant bacteria.
MATERIALS AND METHODS
Bacterial plasmids, strains, and growth conditions. Plasmids and strains used in this study are
detailed in Table S2 in the supplemental material. Cultures were grown at 37°C using Lennox broth/agar unless
otherwise noted. The following antibiotic concentrations were used when appropriate: 10 m g/mL chloramphenicol, 100 m g/mL ampicillin, 30 m g/mL apramycin, or 50 m g/mL zeocin for E. coli and 10 m g/mL chloramphenicol, 50 m g/mL apramycin, 50 m g/mL zeocin, or 300 m g/mL hygromycin B for A. baumannii.
Generation of constructs used in this study. Plasmids and primers used in this study are detailed
in Tables S2 and S3, respectively. Detailed information for construction of plasmids and strains used in the
study is provided in the supplemental material.
Murine infection experiments. Animal experiments were approved by the Washington University
Institutional Animal Care and Use Committee. The murine CAUTI model was performed as previously described
(10). Brieﬂy, 6- to 8-week-old female C57BL/6 mice (Charles River Laboratories, Wilmington, MA) anesthetized
with 4% isoﬂurane were implanted transurethrally with a 4- to 5-mm piece of silicon tubing (catheter). Oncepassaged statically grown bacterial strains were washed twice and resuspended in phosphate-buffered saline
(PBS). Mice were then transurethrally inoculated with 50 m L of the bacterial suspension containing 2  108
CFU. At 24 h postinfection, mice were sacriﬁced, and bacterial load on catheters and in bladders were quantiﬁed by serial dilution plating.
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Proteomic analysis of the T2SS-dependent secretome. Bacterial culture conditions, secreted protein enrichment, digestion of secretome samples, and liquid chromatography-mass spectrometry analysis of
secretome samples were as previously described (101). Details are provided in the supplemental material.
Immunoblot analyses. Bacterial whole-cell lysate preparation and trichloroacetic acid precipitation
of supernatant fractions from mid-exponential cultures was performed as previously described (24, 104).
Indicated fractions were separated by SDS-PAGE, transferred to a nitrocellulose membrane, and proteins
of interest were probed using polyclonal rabbit anti-His6 (1:2,000; Invitrogen, Waltham, MA) and monoclonal mouse anti-RNAP (1:3,500; BioLegend, San Diego, CA). IRDye-conjugated anti-mouse IgG and
anti-rabbit IgG were used as secondary antibodies (1:5,000 for each; LI-COR Biosciences, Lincoln, NE),
and blots were visualized with the Odyssey CLx imaging system (LI-COR Biosciences).
Proteinase K accessibility assays. Proteinase K accessibility assays were performed as previously
described, with some modiﬁcation (105). Stationary-phase cultures were pelleted and resuspended in PBS supplemented with 5 mM MgCl2 to an optical density at 600 nm (OD600) of 2.5. Bacterial suspensions were treated
with 200 m g/mL proteinase K (GoldBio, Olivette, MO) or sham treated with an equal volume of deionized water
in the presence or absence of 2% Triton X-100 (Sigma-Aldrich, St. Louis, MO) at 37°C for 15 min. Digestion was
terminated by addition of 1 mM phenylmethylsulfonyl ﬂuoride (Amresco LLC, Salon, OH), Laemmli buffer was
added to a concentration of 1, and samples were boiled for 10 min. 10-m L samples of these preparations
were separated by SDS-PAGE, and immunoblotting was performed as described above.
Expression and puriﬁcation of recombinant InvL. To generate recombinant protein for antibody
generation, full-length InvL with a C-terminal His10 tag was expressed from pET-22b(1)::invL-his10 in
Rosetta-gami 2(DE3) cells (Novagen, Madison, WI) using ZYM-5052 autoinducible medium for 72 h at 20°C
(106). Cells were then lysed using a CF1 cell disrupter (Constant Systems Ltd., Daventry, UK). Following cell
lysis, recombinant InvL was puriﬁed from the insoluble fraction by Ni-nitrilotriacetic acid afﬁnity chromatography as previously described (107). Puriﬁed protein was then used by Antibody Research Corporation (St.
Peters, MO) to generate polyclonal rabbit antibody.
To generate soluble recombinant InvL for ELISA (described below), InvL lacking the N-terminal signal
sequence (as determined by SignalP 5.0) was expressed with a C-terminal His10 tag from pET-22b(1)::
invL-his10(-SS) in Rosetta-gami 2(DE3) cells by addition of 1 mM isopropyl- b -D-thiogalactopyranoside for
3 h at 37°C (41). Cells were then lysed as described above, and recombinant InvL was puriﬁed from the
soluble fraction using the procedure previously described with the exception that buffers were not supplemented with 0.3% N-lauryl-sarcosine (107).
ELISAs. ELISAs were based on a previously described protocol (50). Detailed protocol information
can be found in the supplemental material.
Eukaryotic cell adhesion assays. Cell adhesion assays were performed with MDCK and 5637 cells
cultured in Dulbecco's Modiﬁed Eagle Medium (DMEM) and Roswell Park Memorial Institute 1640 (RPMI1640) (Gibco, Dublin, Ireland) supplemented with 10% heat-inactivated fetal bovine serum, respectively.
105 MDCK and 3  105 5637 cells (amounts determined to form conﬂuent monolayers) were plated in
48-well Nunclon Delta cell culture–treated surface plates (ThermoFisher Scientiﬁc) overnight at 37°C
with 5% CO2. Stationary-phase A. baumannii strains were pelleted at 5,432  g for 5 min and resuspended in PBS. Following one more spin, bacteria were resuspended in the appropriate cell culture
media, and 500 m L of suspension at the indicated MOI was added to the appropriate wells. Plates were
then centrifuged at 200  g and incubated at 37°C with 5% CO2 for 1 h to allow adhesion. Wells were
subsequently washed three times with 500 m L PBS, cells were resuspended in 0.05% Triton X-100 in PBS,
and serial dilution plating was performed to quantify bacteria. Concurrently, to quantify intracellular
bacteria after the 1 h of incubation and washing, the appropriate cell culture medium supplemented
with 50 m g/mL colistin was added for 1 h. After washing in PBS, cells were resuspended in 0.05% Triton
X-100 in PBS, and serial dilution plating was performed to quantify bacteria.
Bioinformatic analysis of InvL distribution. Ortholog searches were performed across a database
of 3,052 Acinetobacter genomes obtained from NCBI RefSeq as previously described (65). Brieﬂy, the collection
of orthologous groups that resulted from an all versus all ortholog search using OMA was screened to associate the group that harbors a particular protein sequence of interest (108). The sequences of the associated
group collectively served to train a model for the targeted ortholog search across the full database of genomes.
The proteins of interest comprise the translated sequences of D1G37_RS04395 (InvL), D1G37_RS0440,
D1G37_RS04390, and A1S_3863. Since the subset of genomes used by Djahanschiri et al. did not include the
strain UPAB1, the orthologs identiﬁed in the strain MDR-TJ via a reciprocal best blast hit approach were used
to associate orthologous groups (65). The resulting presence/absence matrix together with the genus’ phylogeny served as the input for Vicinator v0.32 (https://github.com/BIONF/Vicinator) to trace the microsynteny of
the invL locus based on MDR-TJ and ATCC 17978 as the reference genomes.
Data availability. The MS data and search results have been deposited into the PRIDE ProteomeXchange
Consortium repository and can be accessed using the accession numbers PXD030460 and PXD030491 (102,
103). All other data are provided within the text or supplemental material.
Statistical methods. All statistical analyses were performed using GraphPad Prism version 9.

SUPPLEMENTAL MATERIAL
Supplemental material is available online only.
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FIG S1, TIF ﬁle, 1.1 MB.
FIG S2, TIF ﬁle, 0.9 MB.
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